EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Karen A Autio iD, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang iD, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan iD, Stephane Billotte und 12 weitere

Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e005702

DOI: 10.1136/jitc-2022-005702 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.03.2023. Verfasst von Karen A Autio und 23 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York, USA autiok@mskcc.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Vaccines. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).

Methods

For dose escalation, patients with mCRPC received intramuscular PrCa VBIR (adenovirus vector and plasmid DNA expressing prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate stem cell antigen (PSCA)) with or without immune checkpoint inhibitors (ICIs, tremelimumab 40 or 80 mg with or without sasanlimab 130 or 300 mg, both subcutaneous). For dose expansion, patients with mCRPC received recommended phase 2 dose (RP2D) of PrCa VBIR plus tremelimumab 80 mg and sasanlimab 300 mg; patients with BCR received PrCa VBIR plus tremelimumab 80 mg (Cohort 1B-BCR) or tremelimumab 80 mg plus sasanlimab 130 mg (Cohort 5B-BCR) without androgen deprivation therapy (ADT). The primary endpoint was safety.

Results

Ninety-one patients were treated in dose escalation (mCRPC=38) and expansion (BCR=35, mCRPC=18). Overall, treatment-related and immune-related adverse events occurred in 64 (70.3%) and 39 (42.9%) patients, with fatigue (40.7%), influenza-like illness (30.8%), diarrhea (23.1%), and immune-related thyroid dysfunction (19.8%) and rash (15.4%), as the most common. In patients with mCRPC, the objective response rate (ORR, 95% CI) was 5.6% (1.2% to 15.4%) and the median radiographic progression-free survival (rPFS) was 5.6 (3.5 to not estimable) months for all; the ORR was 16.7% (3.6% to 41.4%) and 6-month rPFS rate was 45.5% (24.9% to 64.1%) for those who received RP2D with measurable disease (n=18). 7.4% of patients with mCRPC achieved a ≥50% decline in baseline PSA (PSA-50), with a median duration of 4.6 (1.2–45.2) months. In patients with BCR, 9 (25.7%) achieved PSA-50; the median duration of PSA response was 3.9 (1.9–4.2) and 10.1 (6.9–28.8) months for Cohorts 5B-BCR and 1B-BCR. Overall, antigen specific T-cell response was 88.0% to PSMA, 84.0% to PSA, and 80.0% to PSCA.

Conclusions

PrCa VBIR overall demonstrated safety signals similar to other ICI combination trials; significant side effects were seen in some patients with BCR. It stimulated antigen-specific immunity across all cohorts and resulted in modest antitumor activity in patients with BCR without using ADT. Trial registration number NCT02616185 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantVaccinesMaleHumansDocetaxelProstate-Specific AntigenAndrogen AntagonistsImmunotherapyHormones

Stichwörter der Autor:innen

immunogenicity, vaccineprostatic neoplasmstherapies, Investigationalvaccination

Substanzen

DocetaxelProstate-Specific AntigenAndrogen AntagonistsVaccinesHormones

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, New York, USA autiok@mskcc.org.
  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Urology Cancer Center, Omaha, Nebraska, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Duke Cancer Institute, Durham, North Carolina, USA.
  • UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Karen A Autio, Tian Zhang, Ravi A Madan

Förderung

  • NCI NIH HHS
  • Pfizer

Zitieren

APA

Autio, K. A., Higano, C. S., Nordquist, L., Appleman, L. J., Zhang, T., Zhu, X. H., Babiker, H., Vogelzang, N. J., Prasad, S. M., Schweizer, M. T., Madan, R. A., Billotte, S., Cavazos, N., Bogg, O., Li, R., Chan, K., Cho, H., Kaneda, M., Wang, I. M., …, & Petrylak, D. P. (2023). First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer, 11(3), e005702. https://doi.org/10.1136/jitc-2022-005702

Vancouver

Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, et al. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer. 2023;11(3):e005702. doi:10.1136/jitc-2022-005702

BibTeX
@article{Autio2023,
  author = {Autio, Karen A and Higano, Celestia S and Nordquist, Luke and Appleman, Leonard J and Zhang, Tian and Zhu, Xin-Hua and Babiker, Hani and Vogelzang, Nicholas J and Prasad, Sandip M and Schweizer, Michael T and Madan, Ravi A and Billotte, Stephane and Cavazos, Nora and Bogg, Orlaith and Li, Ray and Chan, Kam and Cho, Helen and Kaneda, Megan and Wang, I-Ming and Zheng, Jenny and Tang, Szu-Yu and Hollingsworth, Robert and Kern, Kenneth A and Petrylak, Daniel P},
  title = {First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {e005702},
  doi = {10.1136/jitc-2022-005702}
}
Kostenlos starten →